SUN-P107: Parenteral Omega 3 Significantly Reduces Myeloid-Derived Suppressor Cells in Palliative Pancreatic Patients Receiving Gemcitabine and Intravenous Omega 3 Compared to Patients Receiving Gemcitabine only Treatment

Targeting myeloid-derived suppressor cells for cancer immunotherapy

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells with an immune suppressive phenotype. They represent a critical component of the immune suppressive niche described in cancer, where they support immune escape and tumor progression through direct effects on both the innate and adaptive immune responses, largely by contributing to maintenance of a high oxidative stress environment. The number of MDSCs positively correlates with protumoral activity, and often diminishes the effectiveness of immunotherapies, which is particularly problematic with the emergence of personalized medicine. Approaches targeting MDSCs showed promising results in preclinical studies and are under active investigation in clinical trials in combination with various immune checkpoint inhibitors. In this review, we discuss MDSC targets and therapeutic approaches targeting MDSC that have the aim of enhancing the existing tumor therapies.